GSK pharma head flags need for speed in high-pressure drug market

LONDON (Reuters) - Doing things one at a time in drug development is not a luxury that GlaxoSmithKline can afford any longer, the head of pharmaceuticals at Britain's largest drugmaker told Reuters.Luke Miels, who joined GSK in September 2017 after a contract dispute with his former employer AstraZeneca, said picking the most promising projects and developing them quickly now takes precedence over spreading the risk of failure."In the past, 10 programmes were chosen, a budget for eight was..